E
Annovis Bio, Inc. ANVS
$4.71 $0.061.18% NYSE
Recommendation
Prev Close
$4.65
Volume
327,742
Avg Vol (90D)
1,310,297
Market Cap
$123.24M
Dividend & Yield
--
52-Week Range
$1.11 - $6.61
P/E (TTM)
--
EPS (TTM)
-$1.49
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Annovis Bio (ANVS, $4.41) RSI Indicator left the overbought zone on December 02, 2025
12/3/2025 - Tickeron - Stocks
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
12/3/2025 - Globe Newswire
Annovis Bio, Inc. (NYSE:ANVS) Receives Consensus Rating of "Hold" from Brokerages
12/2/2025 - MarketBeat
Michael Hoffman Acquires 39,200 Shares of Annovis Bio (NYSE:ANVS) Stock
11/26/2025 - MarketBeat
Annovis Bio (ANVS, $4.82) price may drop as it broke higher Bollinger Band on Nov 25, 2025
11/26/2025 - Tickeron - Stocks
Michael Hoffman Buys 39,200 Shares of Annovis Bio (NYSE:ANVS) Stock
11/26/2025 - MarketBeat
Annovis Announces Two Presentations at the CTAD 2025 Conference
11/24/2025 - Globe Newswire
Annovis Bio (NYSE:ANVS) Director Michael Hoffman Purchases 20,000 Shares
11/23/2025 - MarketBeat
Annovis Bio (NYSE:ANVS) Director Michael Hoffman Purchases 20,000 Shares
11/22/2025 - MarketBeat
Annovis Bio (NYSE:ANVS) Director Michael Hoffman Purchases 20,000 Shares
11/22/2025 - Ticker Report
Annovis Bio (ANVS, $3.88) Aroon Indicator entered an Uptrend on November 20, 2025.
11/21/2025 - Tickeron - Stocks
Insider Buying: Annovis Bio (NYSE:ANVS) Director Acquires 15,000 Shares of Stock
11/19/2025 - MarketBeat
Best Penny Stocks To Watch Now - November 17th
11/18/2025 - MarketBeat
Annovis Bio (ANVS) Schedules Key FDA Meeting for Parkinson's Treatment
11/18/2025 - GuruFocus
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
11/18/2025 - Globe Newswire
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
11/18/2025 - Globe Newswire
Annovis Bio Stock Jumps 37% On New Parkinson's Disease Data
11/17/2025 - RTT News - Momentum Stocks
Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients
11/17/2025 - Benzinga
Annovis Bio (ANVS) Highlights Positive Data on Buntanetap in Parkinson's Treatment
11/17/2025 - GuruFocus
Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson's
11/17/2025 - The Fly
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
11/17/2025 - Globe Newswire
Insider Buying: Annovis Bio (NYSE:ANVS) Director Purchases $2,000,000.50 in Stock
11/15/2025 - Ticker Report
Annovis Bio (NYSE:ANVS) Posts Earnings Results, Misses Expectations By $0.01 EPS
11/14/2025 - MarketBeat
Insider Buying: Annovis Bio (NYSE:ANVS) CEO Acquires $200,000.05 in Stock
11/13/2025 - MarketBeat
Insider Buying: Annovis Bio (NYSE:ANVS) Director Purchases 975,610 Shares of Stock
11/13/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$26.72M
Net Income (TTM)
-$24.88M
Balance Sheet
Total Assets (Q)
$17.19M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$4.03M
Book Value Per Share (Q)
$0.6517
Cash Flow
Cash from Operations (TTM)
-$24.98M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$27.63M
Net Change in Cash (TTM)
$2.65M
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 16 and 20 (est)
Price History
Loading...
Beta
1.60
7-Day Total Return
15.04%
30-Day Total Return
131.77%
60-Day Total Return
103.68%
90-Day Total Return
76.88%
Year to Date Total Return
-7.93%
1-Year Total Return
-21.32%
2-Year Total Return
-52.23%
3-Year Total Return
-61.90%
5-Year Total Return
-20.53%
52-week Low
Apr 09, 2025 - $1.11
52-week High
Dec 04, 2024 - $6.61
Valuation
Market Cap
$123.24M - Micro Cap
Enterprise Value
$107.95M
Price/Sales (TTM)
--
Price/Book (Q)
7.14
Dividends and Shares
Shares Outstanding
19.69
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.annovisbio.com
Phone Number
484 875 3192
Address
101 Lindenwood Drive
Malvern, PA 19355
Country
United States
Year Founded
2008
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase... more
NYSE 12/04/2025 1:21PM Eastern Quotes delayed